[Factors with insulin-like effects: IGF-I and GLP-1].
In the submitted review the author discusses two substances secreted into the circulation which can similarly as insulin lower the blood sugar level. These substances are IGF-I (insulin-like growth factor I) and GLP (glucagon-like peptide). While in case of the former it is not certain whether it participates in the glucose homeostasis, this is beyond doubt in the latter. IGF-I prepared by the recombinant technique can be used therapeutically in cases of insulin resistance caused by a receptor or postreceptor disorder, because it may act via its own receptor. Side-effects after larger doses are a problem. GLP-1, the use of which would be useful in type 2 diabetics as it stimulates insulin secretion, is not used so far in therapy because hitherto prepared preparations have a very short period of a effectiveness.
D001786:Blood Glucose / Q000378:metabolism; D005934:Glucagon / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007333:Insulin Resistance; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D010187:Pancreatic Hormones / Q000502:physiology / Q000627:therapeutic use; D010446:Peptide Fragments / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use; D011498:Protein Precursors / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use
D001786:Blood Glucose; D010187:Pancreatic Hormones; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D007334:Insulin-Like Growth Factor I; D052216:Glucagon-Like Peptide 1; D005934:Glucagon
Působky s inzulinovým úcinkem: IGF-I a GLP-1.